Clinical efficacy of RLT to assess OS and PFS using 177Lu DOTATATE, 90Y DOTATATE, and a mixture of both in patients with advanced, unresectable, progressive rectal NET – A retrospective analysis

#4589

Introduction: Retrospective, single-arm, open-label, case series study evaluating the efficacy of different types of radioligand therapy (RLT): 177Lu, 90Y DOTATATE, or mix of both used in advanced, unresectable progressive rectal NETG1/G2.

Aim(s): The primary endpoint overall survival (OS). Secondary endpoint progression-free survival (PFS) based on local RECIST 1.1.

Materials and methods: A group of 24 patients with unresectable, progressive disease stage prior to RLT. All of them with histopathologic confirmation of rectal NETG1/G2. RLT used 90Y, 177Lu DOTATATE or mixture of both. Mean age of subjects 58.8 years, male 10; G1=7 & G2=17. Treatment response evaluated by clinical assessment. PFS based on local RECIST 1.1 and OS during clinical follow-up.

Conference:

Presenting Author: Ćwikła J

Authors: Kolasińska-Ćwikla A, Sankowski A, Pałucki J, Sekelcka N, Ćwikła J,

Keywords: Rectal Neuroendocrine Tumour, SST Receptor, Radioligand Therapy (RLT),